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Long-Term Corticosteroid-Sparing Immunosuppression for
Cardiac Sarcoidosis
David G. Rosenthal, MD; Purvi Parwani, MD; Tyler O. Murray, MD; Bradley J. Petek, MD; Bryan S. Benn, MD; Teresa De Marco, MD;
Edward P. Gerstenfeld, MD; Munir Janmohamed, MD; Liviu Klein, MD, MS; Byron K. Lee, MD; Joshua D. Moss, MD;
Melvin M. Scheinman, MD; Henry H. Hsia, MD; Van Selby, MD; Laura L. Koth, MD; Miguel H. Pampaloni, MD, PhD; Julie Zikherman, MD;
Vasanth Vedantham, MD, PhD
Background-—Long-term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of
long-term corticosteroid-sparing immunosuppression in CS is unknown. The goal of this study was to assess the efficacy of
methotrexate with or without adalimumab for long-term disease suppression in CS, and to assess recurrence and adverse event
rates after immunosuppression discontinuation.
Methods and Results-—Retrospective chart review identified treatment-naive CS patients at a single academic medical center who
received corticosteroid-sparing maintenance therapy. Demographics, cardiac uptake of 18-fluorodeoxyglucose, and adverse
cardiac events were compared before and during treatment and between those with persistent or interrupted immunosuppression.
Twenty-eight CS patients were followed for a mean 4.1 (SD 1.5) years. Twenty-five patients received 4 to 8 weeks of high-dose
prednisone (>30 mg/day), followed by taper and maintenance therapy with methotrexatelow-dose prednisone (low-dose
prednisone, <10 mg/day). Adalimumab was added in 19 patients with persistently active CS or in those with intolerance to
methotrexate. Methotrexatelow-dose prednisone resulted in initial reduction (88%) or elimination (60%) of 18-fluorodeoxyglucose
uptake, and patients receiving adalimumab-containing regimens experienced improved (84%) or resolved (63%) 18-
fluorodeoxyglucose uptake. Radiologic relapse occurred in 8 of 9 patients after immunosuppression cessation, 4 patients on
methotrexate-containing regimens, and in no patients on adalimumab-containing regimens.
Conclusions-—Corticosteroid-sparing regimens containing methotrexate with or without adalimumab is an effective maintenance
therapy in patients after an initial response is confirmed. Disease recurrence in patients on and off immunosuppression support
need for ongoing radiologic surveillance regardless of immunosuppression regimen. ( J Am Heart Assoc. 2019;8:e010952. DOI:
10.1161/JAHA.118.010952.)
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C ardiac sarcoidosis (CS) is an infiltrative cardiomyopathycharacterized by granulomatous inflammation that can
occur in patients without overt clinical manifestations, but
often presents with ventricular tachyarrhythmia (VT), conduc-
tion system disease, and/or heart failure.1,2 Although diag-
nosis of CS can be challenging, with wider use of cardiac
magnetic resonance imaging and 18-fluorodeoxyglucose
positron emission tomography (18F-FDG PET), CS is now
increasingly recognized as an important cause of previously
unexplained atrioventricular block, VT, and non-ischemic
cardiomyopathy.3,4 Furthermore, as more patients with sys-
temic sarcoidosis are actively screened for subclinical cardiac
involvement, CS is increasingly diagnosed in asymptomatic
patients.5
Immunosuppression with corticosteroids or other agents is
currently the standard of care for treatment of symptomatic
active CS, with some centers also recommending treatment
of asymptomatic CS patients, since suppression of active
inflammation may prevent the development of myocardial
fibrosis.1,6–10 While retrospective studies have provided
evidence that immunosuppression reduces mortality and is
associated with reduction in VT burden, reversal of
From the Divisions of Cardiology (D.G.R., P.P., T.O.M., T.D.M., E.P.G., M.J.,
L.K., B.K.L., J.D.M., M.M.S., H.H.H., V.S., V.V.), Rheumatology (J.Z.), and
Pulmonary and Critical Care (B.S.B., L.L.K.), Department of Medicine and
Division of Nuclear Medicine, Department of Radiology (M.H.P.), University of
California, San Francisco, San Francisco, CA; Department of Medicine,
Massachusetts General Hospital, Boston, MA (B.J.P.).
Correspondence to: Vasanth Vedantham, MD, PhD, Cardiology Division,
Department of Medicine, University of California, San Francisco, 555 Mission
Bay Blvd South, SCVRB - 352M, San Francisco, CA94158. E-mail: vasanth.vedan-
tham@ucsf.edu and Julie Zikherman,MD,DepartmentofMedicine, Rheumatology
Division, University of California, San Francisco, 513 Parnassus Avenue, HSW-
1201A, San Francisco, CA 94143. E-mail: julie.zikherman@ucsf.edu
Received September 24, 2018; accepted July 3, 2019.
ª 2019 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use, distribu-
tion and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.118.010952 Journal of the American Heart Association 1
ORIGINAL RESEARCH
Atrioventricular block, and improvement in left ventricular
ejection fraction,4,7,11–16 prolonged use of high-dose corti-
costeroids confers significant risks and impairs quality of
life.17–21 In addition, there are no data investigating the
efficacy and long-term outcomes of immunosuppressive
therapy in those with asymptomatic CS or quiescent disease,
so aggressively treating this group of patients could theoret-
ically expose them to medication side effects without
providing clear benefits.22 For these reasons, balancing the
desire for long-term disease suppression with the risks of
medication side effects can be challenging in clinical practice,
particularly for patients with long-term quiescent disease on
immunosuppressive therapy. Although the current consensus
is that immunosuppression is indicated for treatment of CS,
there is no consensus on the appropriate dosage and the
optimal duration of treatment with corticosteroids, nor on
potential roles of steroid-sparing agents in CS.4,19,23–28 Thus
far, no randomized controlled trials have been performed
comparing different immunosuppressive treatment regimens
for CS, resulting in substantial heterogeneity among different
treatment sites and the lack of evidence-based guidelines on
duration and type of treatment (Table 1).27,29–39
In this context, answering 2 key questions could help to
clarify the utility of different treatment regimens and ultimately
to design appropriate randomized trials: (1) Are steroid-sparing
immunosuppressive agents effective for maintaining long-
term disease quiescence in CS? (2) In those patients with
adequate disease control, what is the likelihood of disease
recurrence after discontinuation of immunosuppression? The
goal of this study is to address these 2 questions using a
retrospective, single center series of patients who were treated
for newly diagnosed CS with short-duration high dose
corticosteroids followed by long-term methotrexate with or
without adalimumab. A subset of these patients chose to
discontinue immunosuppression after achieving remission,
permitting us to evaluate the frequency of clinical and radiologic
CS recurrence after cessation of immunosuppression therapy.
Methods
Study Population
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Patients were referred for diagnosis and management of CS to
the University of California San Francisco Medical Center
between January 2009 and November 2018. A histologic or
clinical CS diagnosis was ascertained per 2017 Japanese
Society of Cardiology expert consensus diagnostic criteria.43
Inclusion criteria were as follows: age ≥18 years with a
diagnosis of confirmed CS; initial treatment with 4 to 8 weeks
of high dose prednisone (>30 mg/day), followed by mainte-
nance therapy with oral methotrexatelow-dose prednisone
(LDP, <10 mg/day)adalimumab; at least 2 consecutive pre-
and post-treatment PET scans 6 months apart. Those with
unavailable or insufficient studies, follow-up <6 months, and
those treated with immunosuppression before presentation to
our institution were excluded. The requirement for subject
informed consent was waived.
Clinical Characteristics
Baseline demographics, medical history, and ECG character-
istics at the time of CS diagnosis were gathered by utilizing
the electronic medical record. Demographics investigated
included age, sex, and body mass index. Medical history
included cardiovascular risk factors such as hypertension,
hyperlipidemia, diabetes mellitus, coronary artery disease, as
well as the presence of extra-cardiac sarcoidosis. Baseline
ECG characteristics were determined from available ECGs,
ambulatory cardiac monitors, and device interrogations.
Prevalent cardiac disease included sustained atrial arrhyth-
mias (atrial fibrillation, atrial flutter, or supraventricular
tachycardia requiring treatment), high-grade atrioventricular
block (defined as Mobitz II or higher), clinical heart failure, and
sustained ventricular arrhythmias (defined as VT/VF lasting
>30 seconds, appropriate implanted cardioverter defibrillator
therapy, or VT storm). High-grade atrioventricular block was
identified by chart review, ECG, or review of underlying rhythm
on device interrogation. In addition, the minimum and
maximum percent pacing was recorded for each patient.
Symptomatic heart failure was defined as an inpatient
hospitalization for acute decompensated heart failure, wors-
ening functional status consistent with heart failure, or
decline in left ventricular ejection fraction by at least 10%
Clinical Perspective
What Is New?
• A corticosteroid-sparing strategy using methotrexate with or
without adalimumab is an effective maintenance therapy for
treatment of active cardiac sarcoidosis.
• Discontinuation of immunosuppression is associated with a
high rate of radiologic relapse and ventricular tachycardia.
What Are the Clinical Implications?
• Treatment of cardiac sarcoidosis with immunosuppression
remains a cornerstone of therapy, and these data provide
evidence that stable immunosuppression can be achieved
with low doses of prednisone combined with other agents.
• These findings can be used to guide future prospective and
randomized studies to investigate the optimal immunosup-
pression regimen and duration of therapy.
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on consecutive echocardiograms. VT storm was defined as ≥2
VT/VF episodes within 24 hours. VF was defined as disorga-
nized ventricular electrical activity resulting in cardiac arrest.
This study is in accordance with requirements approved by
the University of California, San Francisco Institutional Review
Board, and all procedures were performed per University of
California, San Francisco institutional guidelines (#14-15430).
18F-FDG PET
Serial 18F-FDG PET scans were performed at 6-month
intervals until patients were clinically stable, and after that
were performed annually for surveillance or in response to a
change in therapy or clinical status. More specifically, PET 1
was performed before initiation of immunosuppression at the
time of CS diagnosis, and PET 2 was obtained on maintenance
immunosuppression (ie, following taper of initial high-dose
prednisone). Subsequent PET scans were obtained in patients
after any change in maintenance immunosuppressive regimen
(including switch to adalimumab-containing regimen), after
immunosuppression discontinuation in applicable patients, or
in patients with a clinical change in status on relapse. Patients
were studied using a whole-body PET scanner with 3D
acquisition (Siemens HR plus, Erlangene, Germany). External
germanium-68 sources were used for attenuation correction.
All patients prepared for the scan by consuming a high-fat,
limited or non-carbohydrate diet for a minimum of 24 hours
before the exam and were advised to fast for 12 hours before
the procedure per recent guideline recommendations.44
Resting myocardial perfusion was assessed after using the
intravenous administration of 40 mCI of 82-rubidium. Blood
glucose level was confirmed before the injection of FDG (7–
10 mCi) to ensure euglycemia. Approximately 10 mci of 18F-
FDG was injected intravenously. Metabolic images were
Table 1. Previously Studied Immunosuppressive Regimens in Cardiac Sarcoidosis
Authors Year n Country
High-Dose
Immunosuppression Taper Duration
Low-Dose
Immunosuppression
Corticosteroid-
Sparing Agent
Immunosuppression
Discontinuation
Ahmadian et al29 2017 17 United States Not reported Not reported Not reported No No*
Banba et al11 2007 15 United States Variable 6 to 12 mo Prednisone 5 to
10 mg/d
No No
Ballul et al40 2016 36 France Prednisone
60 mg/d
Not reported Not reported Multiple No
Chapelon-Abric
et al24,30
2004, 2017 41,
59
France IV prednisolone
15 mg/kg93 d
Variable Not reported Multiple Yes
Chiu et al25 2005 43 Japan Prednisone
60 mg QOD
2 mo Prednisone
10 mg/d
No No
Fussner et al31 2018 91 United States Prednisone 40 to
60 mg/d
Variable Variable Multiple No
Futamatsu
et al26
2006 21 Japan 5 to 60 mg
prednisone/d
Variable Prednisone 0 to
20 mg/d
No No
Hiramatsu et al41 2005 49 Japan Prednisone 30 to
60 mg/d
0.5 to 1 mo Prednisone 5 to
10 mg/d
No No
Kato et al32 2003 20 Japan Variable Variable Variable No No
Kudoh et al33 2010 10 Japan Not reported Not reported Not reported No No
Lee et al34 2017 16 United States Not reported Variable Not reported No No
Muser et al39 2018 20 United States Not reported Variable Not reported Methotrexate No
Nagai et al4,35,36 2014, 2015,
2016
17 to
61
Japan Prednisone 30 to
40 mg/d
Variable Prednisolone 5
to 15 mg/d
Methotrexate Yes
Osborne et al37 2014 23 United States Not reported Variable Not reported No No
Padala et al38 2016 30 United States Variable Variable Variable No No
Yazaki et al27 2001 95 Japan Prednisone 30 to
60 mg/d
Variable Prednisone 5 to
15 mg/d
No No
Yodogawa
et al28,42
2011, 2013 31,
15
Japan Prednisone
30 mg/d
6 mo Prednisone 5 to
10 mg/d
No No
Prior studies investigating the efficacy of specific immunosuppression regimens. IV indicates intravenous.
*4 of 6 subjects in the study by Ahmadian et al demonstrated worsening qualitative FDG uptake in those who reduced immunosuppression.
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acquired after 45 to 60 minutes of injection of 18F-FDG,
which resulted in adequate diagnostic images. Limited whole
body 18F-FDG images were taken from the vertex to mid-
thigh in all the patients. The maximal standardized uptake
value (SUVmax) was reported as the highest voxel value with
the region of interest, and the ratio myocardial SUVmax to
liver SUVmax was determined (reported as “normalized
SUVmax” to facilitate comparison between studies). All 3
image sets were reconstructed into transaxial images and
resliced into standard data sets for image display. The
radiologist was masked to patient treatment and clinical
status.
Statistical Analysis
Patients were retrospectively divided into those who did and
did not discontinue immunosuppression during clinical follow-
up, and baseline characteristics were reported. Differences in
radiologic disease activity (PET 1) and cardiac manifestations
present at the time of CS diagnosis were reported in each
group. Following CS diagnosis, the incidence of persistent
radiologic disease activity (PET 2) and adverse cardiac events
including VT, symptomatic heart failure, and atrioventricular
block were reported and compared between groups. In
addition, CS activity (PET 3) and clinical manifestations were
compared in patients with continuous immunosuppression to
those after immunosuppression discontinuation.
Each PET scan was qualitatively reported as positive (18F-
FDG avidity in a pattern consistent with CS), improved
(myocardial 18F-FDG uptake present but qualitatively reduced
compared with the prior scan), or negative (no myocardial 18F-
FDG uptake). In addition, a subset of PET scans were subject to
quantification in which software calculated global and regional
cardiacmetabolic activity. Activemyocardial disease sites were
separated from mediastinal blood pool activity. Each scan was
interpreted by an experienced radiologist (M.H.P.). A Wilcoxon
rank sum test was used for comparison between groups
because of non-normally distributed data. A P value of <0.05
was considered statistically significant. Statistical analyses
were performed on Stata (College Station, TX).
Results
Baseline Characteristics
CS was diagnosed in 34 patients referred per 2017 Japanese
Society of Cardiology expert consensus diagnostic criteria,45
and 28 patients ultimately met inclusion criteria for this study.
Patients not included did not have 2 consecutive PET scans
for analysis (n=4), or were initially treated at an outside facility
(n=2). Three patients met clinical criteria for clinical CS, and
25 patients met histologic criteria. Mean follow-up was
4.1 years (SD 1.5 years) after CS diagnosis. Patients were
predominantly young (mean age 52 years), non-black, had few
medical comorbidities, and had frequent baseline ECG
abnormalities at the time of CS diagnosis (Table 2). Three
subjects were black, 3 were Asian, 1 Hispanic, and the
remainder white. The study cohort was highly enriched for
symptomatic patients at time of CS diagnosis, with the
majority (n=22) presenting with cardiac symptoms, 8 pre-
senting with pulmonary symptoms (6 later developed cardiac
symptoms), and only 2 had incidental diagnosis of CS. Two
patients had isolated CS while the remainder had extra-
cardiac sarcoidosis, predominantly pulmonary. Ultimately 9 of
26 patients discontinued immunosuppression after a mean
1.97 years (SD 0.96 years) of continuous therapy because of
medication side effect (n=3) and/or patient preference (n=6).
No significant differences in baseline demographics or history
were observed between patients who discontinued versus
continued immunosuppression, with the exception of a female
predominance of patients who discontinued immunosuppres-
sion (67% versus 32%, Table 2).
Immunosuppression Regimens
Of the 28 patients included in the study, 27 treatment-na€ıve
patients who had positive 18F-FDG-PET scans at baseline (PET
1) received a period of high-dose prednisone (40–60 mg daily,
mean 46.6 mg, SD 9.3 mg) for 4 to 8 weeks (mean
6.8 weeks, SD 2.2 weeks) followed by a taper to <10 mg of
prednisone daily, typically 5 mg daily. Methotrexate was
started at 10 to 15 mg per week and increased by 5 mg
increments every 2 weeks until a dose of 20 mg per week
was reached. One patient was treated with adalimumab
monotherapy without methotrexate or concomitant corticos-
teroids because of previous intolerance both corticosteroids
and methotrexate. By the time of the repeat 18F-FDG PET
scan (median 34.3 weeks, SD 14.5 weeks, range 11.0–
73.8 weeks) after initiating treatment (PET 2), 18 of 28
patients were on LDP (mean 6.4 mg daily, SD 4.6 mg daily)
with methotrexate 20 mg weekly, 7 were on methotrexate
20 mg weekly alone, and 3 were on an adalimumab-contain-
ing regimen. In those with intolerance or contraindications to
methotrexate, the next line agent used was adalimumab
(40 mg subcutaneous injection biweekly) except in patients
with New York Heart Association class III or IV heart failure. In
those patients, once adalimumab was added, the methotrex-
ate dose was concomitantly reduced to 7.5 or 10 mg weekly
(n=8). In patients with persistent disease as assessed by PET
despite methotrexate, the same dose of adalimumab (40 mg
subcutaneous injection biweekly) was added along with
methotrexate 15 mg weekly (n=11). While 19 of 28 patients
maintained indefinite immunosuppression using ≥1 steroid-
sparing agents, immunotherapy was discontinued entirely in 9
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of 28 patients after a period of disease quiescence, per
patient preference, and/or because of medication intolerance
or side effects.
Minor side effects of immunosuppression requiring med-
ication discontinuation or additional medications (eg, insulin
or metformin) occurred in 16 of 28 patients. The most
common side effects were elevated transaminase levels (n=9)
attributed to or exacerbated by methotrexate. All resolved
with reduced dose or cessation of methotrexate. Four patients
on prednisone developed hyperglycemia that required treat-
ment. One patient on methotrexate monotherapy developed
recurrent episodes of diverticulitis although such episodes
both preceded and succeeded methotrexate treatment, and a
patient on methotrexate with adalimumab developed a
presumed lung infection (on imaging) requiring a temporary
cessation of immunosuppression. In addition, there was 1
possible case of pulmonary toxicity (acutely reduced diffusion
capacity on PFTs, but normal chest CT) for which methotrex-
ate was empirically stopped.
Corticosteroid Sparing Therapy and Radiologic CS
Suppression
We defined corticosteroid-sparing therapy as methotrexate
and/or adalimumab with or without concomitant low-dose
prednisone (<10 mg daily). As described above, patients were
preferentially treated initially with prednisone taper and
methotrexate. At the time of first follow-up PET scan, 15 of
25 patients treated primarily with methotrexate achieved
complete resolution of 18F-FDG uptake, 7 experienced partial
resolution of 18F-FDG uptake, and 3 patients experienced
persistent 18F-FDG uptake (Figure 1).
Table 2. Baseline Demographics of Patients With Cardiac Sarcoidosis
Total (n=28) Immunosuppression Discontinued (n=9) No Immunosuppression Discontinuation (n=19)
Demographics
Age, y 52.2 51.3 53.0
Women 12 (42.8%) 6 (66.7%) 6 (31.6%)
Body mass index, kg/m2 28.8 27.4 21.1
Medical history
Hypertension 5 (17.8%) 1 (11.1%) 4 (21.1%)
Hyperlipidemia 3 (10.7%) 1 (11.1%) 2 (10.5%)
Diabetes mellitus 2 (3.6%) 0 2 (10.5%)
Coronary artery disease 1 (3.6%) 0 1 (5.3%)
PPM/ICD 26 (92.9%) 9 (100%) 17 (89.5%)
Extracardiac sarcoidosis 26 (92.9%) 9 (100%) 17 (89.5%)
Lung 21 (72.4%) 5 (55.6%) 16 (84.2%)
Spleen 5 (17.8%) 1 (11.1%) 4 (21.1%)
Lymph nodes 18 (64.3%) 4 (44.4%) 14 (73.7%)
ECG
LBBB 3 (10.7%) 1 (11.1%) 2 (10.5%)
RBBB 12 (42.9%) 5 (55.6%) 7 (36.8%)
1st degree atrioventricular block 11 (39.3%) 3 (33.3%) 8 (42.1%)
Frequent PVCs 16 (57.1%) 6 (66.7%) 10 (52.6%)
Non-sustained VT 10 (35.7%) 3 (33.3%) 7 (36.8%)
Prevalent cardiac manifestations
Atrial arrhythmia 8 (28.6%) 4 (44.4%) 4 (21.1%)
High-grade atrioventricular block 11 (39.2%) 3 (33.3%) 8 (42.1%)
Sudden cardiac arrest 4 (14.3%) 2 (22.2%) 2 (10.5%)
Heart failure 11 (39.3%) 4 (44.4%) 7 (36.8%)
Sustained VT or VF 18 (64.3%) 6 (66.7%) 12 (63.2%)
ICD indicates implanted cardioverter defibrillator; LBBB, left bundle branch block; PPM, permanent pacemaker; RBBB, right bundle branch block; VF, ventricular fibrillation; VT, ventricular
tachycardia; PVCs, premature ventricular contractions.
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Those patients with partial resolution or persistent 18F-
FDG avidity on methotrexate (refractory disease) were treated
with addition of adalimumab, as described above, and further
PET scans were obtained to assess response to treatment
change. Of the remaining 15 complete responders, 4
eventually experienced radiographic relapse while on stable
regimens of methotrexateLDP. Six additional patients
changed immunosuppression regimens because of side
effects and/or personal preference. For these reasons,
adalimumab was used in a total of 19 patients; 12 of 19
experienced complete resolution on PET, another 4 of 19
exhibited partial response, and 3 of 19 remained unrespon-
sive (Figure 1). No subject receiving adalimumab demon-
strated a radiologic CS relapse to date although average
duration of follow-up for adalimumab-treated patients is
shorter than for methotrexate-treated patients as methotrex-
ate was used first line in our cohort.
During cumulative follow-up, 117 total PET scans
were analyzed, 76 of which were obtained on immunosup-
pression. Four studies were excluded because of poor
patient dietary preparation resulting in non-diagnostic image
quality. Overall, 69.7% (53/76) of PET scans on immuno-
suppression demonstrated complete 18F-FDG resolution,
and an additional 15.8% (12/76) demonstrated partial 18F-
FDG resolution, compared with positive 18F-FDG uptake
in 37/41 (90.2%) of PET scans obtained off immuno-
suppression. PETs obtained after immunosuppression
discontinuation demonstrated positive 18F-FDG uptake in
11of 12 scans.
Discontinuation of Immunotherapy for Recurrent
CS
During follow-up, 9 patients ultimately discontinued immuno-
suppression after achieving initial complete resolution of
cardiac inflammation on PET because of medication intoler-
ance or patient preference (Table 3). Three of these patients
discontinued therapy twice. Immunosuppression was stopped
after a mean 32.0 months (SD 9.7 months) of continuous
therapy. Each of these patients underwent a repeat 18F-FDG-
PET scan to assess for disease recurrence (Figure 2). Patients
who discontinued immunosuppression subsequently experi-
enced radiologic CS recurrence by PET in 8 of 9 (88.9%)
patients an average of 8.4 months (SD 2.4 months) after
discontinuation, compared with recurrence in 3 of 19 (15.8%)
patients with uninterrupted immunosuppression.
18/28 patients in our study experienced VT during the
course of their disease before starting immunosuppression.
The pre-treatment incidence of VT was comparable between
patients who continued immunosuppression and those
who discontinued therapy (Table 2). After initial treatment,
3 of 19 (15.8%) patients who remained on uninterrupted
immunosuppression subsequently experienced VT, while 3 of
9 (33.3%) with interrupted immunosuppression experienced
Figure 1. Association between immunosuppression regimen and complete resolution of 18-fluorodeox-
yglucose uptake on positron emission tomography in patients with cardiac sarcoidosis. All patients were
initially treated with a methotrexate-containing regimen except for 2 patients, who were initially treated
with an adalimumab-containing regimen. Persistent, decreased, or no 18-fluorodeoxyglucose resolution in
each patient stratified on maintenance immunosuppression. FDG indicates fluorodeoxyglucose; LDP, low-
dose prednisone; MTX, methotrexate.
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VT after discontinuation of therapy (Table 4). Of note, the time
of observation for patients after discontinuation of immuno-
suppression was much less than for the group with uninter-
rupted immunosuppression; similarly, the length of time over
which patients had VT before treatment was greater still.
One patient developed heart failure while off immunosup-
pression, but overall there was no significant difference in
LVEF assessed by TTE after starting immunosuppression
(53.4% [SD 12.3%] versus 48.7% [SD 11.4%], P=0.14) or after
immunosuppression discontinuation (49.9% [SD 10.2%] ver-
sus 44.4% [SD 13.4%], P=0.77). One patient with an
implantable pacemaker developed permanent atrioventricular
block during the study period, and one patient developed
transient complete heart block following VT ablation that
resolved within 2 weeks. After immunosuppression discon-
tinuation, maximal percent pacing was similar (34.8%, SD
43.0%) to that before immunosuppression discontinuation
(32.1%, SD 36.4%, P=0.71).
Quantification of Myocardial 18F-FDG Uptake
18F-FDG quantification before starting immunosuppression
and after discontinuing immunosuppression was available in
18 of 28 subjects (Figure 3). The remaining subjects were
unavailable because of inaccessible primary data (n=6) and
PET scans performed at outside institutions (n=4). Initiation of
immunosuppression was associated with a decrease in
normalized myocardial SUVmax from a mean of 2.15 (SD
0.73) to 1.07 (SD 0.57, P<0.01). In the 9 subjects who
discontinued immunosuppression, normalized myocardial
SUVmax increased from 0.78 (SD 0.24) to 1.73 (SD 1.07,
P<0.01). Subjects with an initial clinical presentation of
atrioventricular block demonstrated a decrease in mean
SUVmax of 2.81 (SD 0.96) before immunosuppression to 1.53
Table 3. Radiologic Relapse or Cardiac Event in Cardiac Sarcoidosis Patients Stratified by Immunosuppression Regimen
Total Subjects Incomplete Treatment Response Radiologic Relapse Cardiac Event
After immunosuppression discontinuation 9 N/A 8 2
Methotrexate 25 10 4 3 (2 AVB, HF)
Adalimumab-containing 19 7 0 0
Incomplete treatment response is defined as persistent or decreased 18F-FDG uptake after initial treatment with immunosuppression. Radiologic relapse is defined as initial complete
resolution of 18F-FDG on PET, followed by serial increase in 18F-FDG uptake on follow-up scan. HF indicates heart failure; AVB indicates atrioventricular block.
Figure 2. Cardiac sarcoidosis (CS) disease activity determined
by 18-fluorodeoxyglucose positron emission tomography (18F-
FDG PET) throughout treatment course. Serial positron emission
tomography scans obtained in a single patient with different
immunosuppression regimens, with the short-axis view visualized,
from apex to base. The image on top is perfusion imaging, and the
bottom demonstrates 18F-FDG uptake. A, De novo CS: Initial
positron emission tomography demonstrates 18F-FDG uptake in
the anteroseptum with a corresponding perfusion defect (my-
ocardial maximal standardized uptake value [SUVmax]=2.85,
SUVmax/standardized uptake value(liver)=1.08). B, CS suppres-
sion: Complete resolution of 18F-FDG uptake on methotrexate
maintenance therapy, with persistent perfusion defect, consistent
with treated CS with residual scar. There is only mild 18F-FDG
uptake seen in the blood pool (myocardial SUVmax 0.77,
SUVmax/standardized uptake value (liver)=0.31). C, CS recur-
rence: After immunosuppression discontinuation, there is new
18F-FDG uptake in the basal to mid-anterolateral wall with a new
perfusion defect (myocardial SUVmax 4.78, SUVmax/SUV(liver)
=1.53). FDG indicates fluorodeoxyglucose; SUVmax, maximal
standardized uptake value.
Table 4. Ventricular Tachycardia in Cardiac Sarcoidosis by
Immunosuppression Status
VT Incidence
Before immunosuppression 18/28 (64.3%)
On continuous immunosuppression 3/19 (15.7%)
After discontinuation of immunosuppression 3/9 (33.3%)
Of the 28 subjects in this study, 6 had VT before starting immunosuppression. After
starting immunosuppression, 3 of 19 who remained on uninterrupted
immunosuppression developed VT, while 3 of 9 who discontinued immunosuppression
developed VT after interruption of therapy. VT indicates ventricular tachycardia.
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(SD 1.19) after starting immunosuppression, and those
presenting with VT demonstrated a decrease in mean
SUVmax of 2.03 (SD 0.41) to 0.94 (SD 0.18) after starting
immunosuppression.
Discussion
In this report, we present outcomes of corticosteroid-sparing
immunosuppression and frequency of disease recurrence after
cessation of immunosuppression in a single-center cohort of CS
patients followed for several years. Our main findings are that
steroid-sparing therapies utilizing methotrexate and/or adali-
mumab are effective to maintain radiographic disease quies-
cence after taper of prednisone (at least 60% for either regimen),
and that patients with quiescent disease who discontinue
immunosuppression have a significantly increased risk of
exhibiting radiologic recurrence as well as recurrent VT.
Efficacy of Corticosteroid-Sparing Treatment for
Cardiac Sarcoidosis
A strategy using LDP, methotrexate, and/or adalimumab is
associated with a high likelihood of complete resolution or
marked improvement of 18F-FDG uptake in active CS. The
optimal induction therapy, dose, and duration of immunosup-
pressive agents in CS remains incompletely understood and
currently needs to be determined on a case-by-case basis
because of the complexity of achieving immunosuppression
while minimizing adverse medication effects. However, this
study demonstrates that each combination regimen has
substantial efficacy for achieving complete CS remission.
Previously, corticosteroid monotherapy was the mainstay of
treatment for CS.19 However, a recent study demonstrated high
rates of CS recurrence, increased steroid doses, and medica-
tion side effects in those treated with corticosteroid monother-
apy compared with immunosuppression with prednisone and
methotrexate.40 Patients in the aforementioned study were not
routinely surveilled by PET, and exact treatment regimens and
doses were not presented. However, the results of the current
and aforementioned study suggest that immunosuppression in
addition to corticosteroids may be required for persistent CS
suppression. We found that 60% of patients on LDP and
methotrexate therapy exhibited an initial complete radiologic
response, with a mean LDP dose of 6.4 mg/day. However, 4
patients developed radiologic relapse while on methotrexate
therapy despite dosing 20 mg once weekly (consistent with
doses used for treatment of other rheumatologic diseases such
as rheumatoid arthritis).46–48 Furthermore, almost half of
patients treated with methotrexate experienced side effects,
often resulting in dosage decrease and/or discontinuation of
the medication. Given long-term reported relapse rates of
40% in sarcoidosis patients treated with corticosteroid
monotherapy,49 these data collectively support the use of
methotrexate as an initial corticosteroid-sparing agent, albeit
with serial surveillance for side effects and CS relapse.
The efficacy of adalimumab-containing regimens in this study
is notable. Adalimumab is a monoclonal antibody to tumor
necrosis factor-alpha, an important mediator of granulomatous
inflammation, and is an effective treatment for selected patients
with systemic sarcoidosis.50–53 Concerns over the association
between high dose infliximab and worsened heart failure in the
ATTACH (Anti-TNF Therapy Against Congestive Heart Failure)
trial have limited the use of tumor necrosis factor-alpha
blockers in cardiac sarcoidosis.54 Indeed, use of tumor necrosis
factor inhibitors in New York Heart Association class III and IV
heart failure is contraindicated, and high doses of infliximab
(>3 mg/kg) should be used with caution in all patients with
heart failure or reduced EF. However, adalimumab (dosed at
40 mg every 2 weeks) has potential advantages because of
shorter half-life, lower adverse drug events, and improved safety
Figure 3. FDG quantification and immunosuppression status in
cardiac sarcoidosis. A, Normalized maximal standardized uptake
valuefor each subject at the time of cardiac sarcoidosis diagnosis
and after initial immunosuppression treatment. B, In those
subjects who discontinued immunosuppression, normalized max-
imal standardized uptake value is reported before and after
immunosuppression discontinuation. SUV indicates standardized
uptake value; SUVmax, maximal standardized uptake value.
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signal for heart failure in large cohorts of patients treated for
rheumatoid arthritis compared with infliximab.55,56
In the current study, 84% of those who received adal-
imumab-containing regimens demonstrated at least partial
reduction in 18F-FDG uptake, and 63% experienced complete
18F-FDG resolution without drug toxicity. We treated only
patients with New York Heart Association class 1 or 2
symptoms with adalimumab. Although we did not observe a
significant decline in EF or increase in clinical heart failure
among adalimumab-treated patients in our cohort, our duration
of follow-up on this drug was not long and we strongly favor
cautious use of this pharmacologic agent with close monitoring
of heart failure and EF. These findings cannot be directly
compared with the efficacy of those receiving LDP and
methotrexate in this study because several of those patients
who received adalimumab had previously failed methotrexate.
Longer-term follow-up with surveillance PET scans will be
needed to establish whether relapse on adalimumab occurs
and at what rate relative to methotrexate. In addition, it will be
critical to determine long-term effect on EF and New York Heart
Association class, although separating effects of adalimumab
from natural history of heart failure will be challenging without a
clinical trial or a reasonable comparison group (eg, methotrex-
ate-treated patients). Overall, our data support the use of
adalimumab to maintain CS quiescence. Further studies are
needed to determine whether adalimumab can be effective as
part of a first-line treatment strategy.
Immunosuppression Discontinuation in CS
Few studies have investigated clinical outcomes in CS
patients following discontinuation of immunosuppression.
Nagai et al recently published the first data suggesting that
discontinuation of immunosuppression in CS patients was
associated with a reduction of systolic function and increased
mortality during long-term follow-up of almost 10 years.4 Our
data demonstrates that immunosuppression discontinuation
is associated with an increase in clinical and radiographic CS
recurrence even after over 2 years of continuous treatment
with immunosuppression. In conjunction with previous
research demonstrating increased cardiac morbidity and
mortality in patients with active CS,11,57 these data support
prolonged and possibly indefinite use of immunosuppression
in CS patients to prevent disease reactivation, or alternatively
meticulous surveillance with PET scans in those who do
choose to stop immunosuppression.58
Immunosuppression Status and Clinical End
Points in CS
Our results also highlight the increased risk of VT in CS
patients after immunosuppression discontinuation. While
immunosuppression is associated with prevention of left
ventricular remodeling and recovery of atrioventricular nodal
function in active CS,25,28,59 a paucity of data exists
examining long-term follow-up of CS patients who ultimately
discontinue therapy because of high rates of medication side
effects, interactions, and intolerance.21 Patients with contin-
uous immunosuppression experienced less VT compared with
those after immunosuppression discontinuation, corroborat-
ing previous findings.42 The majority of VT episodes were
temporally associated with positive PET scans, suggesting
that the risk of VT after immunosuppression discontinuation is
mediated largely by the presence of active CS.
While VTwasmore commonduring periods of active disease,
multiple events were noted during periods of inactive disease.
These findings are consistent with the hypothesis that VT
associated with inactive disease is mediated by steroid-
unresponsive scar-mediated reentry, while VT occurring during
active or reactivated CS may be because of steroid-responsive
areas of active inflamed and healing myocardium.7,15,41,60,61 VT
in both active and inactive CS frequently requires interventions
in addition to immunosuppression including implanted car-
dioverter defibrillator implantation, anti-arrhythmic medica-
tions and radiofrequency ablation.61,62 Those who do not
tolerate immunosuppression represent a population at high VT
risk—careful monitoring with surveillance PET imaging, and a
low threshold for implanted cardioverter defibrillator implanta-
tion should be considered and investigated prospectively.
Despite the majority of patients with frequently monitored
devices, one patient developed clinical atrioventricular block
while on methotrexate therapy with an associated radio-
graphic relapse. In those with implantable pacemakers, the
burden of ventricular pacing was unchanged after stopping
immunosuppression, which remains a poor surrogate measure
of intermittent atrioventricular block because of heterogeneity
of programming settings, high burden of premature ventri-
cular contractions, and use of anti-arrhythmic drugs. The
relatively shorter follow-up period in the current study likely
explains the lack of heart failure seen in CS patients who
discontinue immunosuppression, as progressive fibrosis is
often a more indolent process.
Limitations and Future Investigations
The major limitations of the current study are the small sample
size and retrospective nature of data collection that precludes
statistical comparisons between specific immunosuppression
regimens, and between those who did and did not discontinue
immunosuppression. The statistical tests that were performed
in this study were univariate and the cohort size was likely
underpowered to detect significant differences between groups
due to limited sample size. In addition, the current study
represents the experience at a single tertiary care institution
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and patient selectionmay suffer from referral bias, supported by
the finding that 60% of patients had sustained VT at initial
presentation of CS. Future work involving multiple centers will
hopefully be able to address specific clinical predictors of
response to specific therapies and to identify clinical risk
markers that could be harbingers of disease recurrence. While
the goal of steroid-sparing treatment was to minimize the
duration of high-dose steroid administration, individual regi-
mens varied and, as such, the ability to investigate specific
agents or duration of treatments in isolation remains limited.19
Future studies should prospectively investigate not only the
efficacy of specific steroid-sparing agents, but also differences
in quality-of-life in patients treated with this strategy compared
with patients treated with escalating doses of steroids. It will
be important to clarify the type of induction therapy, duration
of maintenance therapy, and preferred agents required to
maintain disease quiescence. Further, the patients in the
current study overwhelmingly presented with symptomatic CS,
and all patients in the study had cardiac or extra-cardiac
evidence of sarcoidosis. It will be important to determine
whether our conclusions can be generalized to patients with
incidentally identified CS without histologic confirmation,
particularly given the recent finding that inflammatory
myocarditis is a common and underrecognized cause of
ventricular ectopy, and adverse outcomes may be ameliorated
by immunosuppression.63,64 Despite these inherent limita-
tions, the findings in the current study are provocative and
warrant future prospective investigation.
Conclusions
A steroid-sparing immunosuppressive regimen using metho-
trexate or adalimumab was effective in suppressing myocar-
dial inflammation in CS, and discontinuation of immunosup-
pression was associated with disease recurrence and VT
events. These findings support a strategy of long-term
immunosuppression with steroid-sparing agents for maintain-
ing disease quiescence in CS. Prospective and randomized
data will ultimately be required to determine the optimal
regimen and duration of therapy.
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